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CS15.1 CMV in transplant recipients
B.-H. Tan*. Department of Internal Medicine, Singapore
General Hospital, Singapore
CMV has long been described as the Achilles heel of
organ transplantation. CMV may produce direct effects
such as fever, and end-organ damage, such as retinitis
and colitis. CMV is also thought to produce indirect
effects such as rejection, diabetes, and perhaps even graft
atherosclerosis (in heart transplant recipients). Advances
in viral diagnostics, plus the availabilty of ganciclovir and
valganciclovir, however, have made CMV less fearsome than
it used to be. In this lecture, we will review the data
on both the prophylactic and pre-emptive modes of CMV
prevention in organ transplant recipients, and ask ourselves
if the technology that is now enabling us to measure host
immunity to CMV has a role in clinical management.
CS15.2 Drug design and development against EV71 and
other enteroviruses
T.W. Lin*. State Key Laboratory on Stress Cell Biology,
School of Life Sciences, Xiamen University, China
Enteroviruses are a family of single stranded, positive
sense RNA virus of Picornaviridae. Although most of the
enterovirus-associated diseases are mild and asymptomatic,
some member in the family can cause severe diseases and
death, especially in the young and immunocompromised.
Enteroviruses are the leading cause of aseptic meningitis
which in turn is the most common central nervous
system infection. Enterovirus 71 (EV71), for example,
is an important pathogen besides polioviruses of the
family. It is emerging as the most signiﬁcant neurotropic
enterovirus in some area of the world in outbreaks and
epidemics. This virus circulates in US, and 26% of the
adults tested in a study had antibody. EV71 was the
leading cause of infectious diseases in China in 2010.
The outbreaks of EV71-associated diseases have been
reported in the United States, Australia, Sweden, Japan,
Bulgaria, Hungary, Malaysia, and other countries. It has been
associated with a variety of clinical diseases, including hand,
foot and mouth disease, herpangina, aseptic meningitis,
encephalitis, poliomyelitis-like paralysis, and even fatal
pulmonary edema or hemorrhage. Eneterovirus-associated
disease can be both acute and chronic. The chronic
diseases include dermatomyositis, polymyositis, dilated
cardiomyopathy, and diabetes mellitus. There is an urgent
need to develop therapeutics against EV71 in particular, and
enteroviruses in general.
Upon infection, a polyprotein is translated from the single
open reading in the genome of an enterovirus, which
is processed into mature proteins by virally encoded
proteinases. These proteinases are not only vital to the
propagation of the virus but important factors in limiting
host defense against the virus infection as well. We carry
out structure-based screening, design, and development
of inhibitors against the enterovirus infection using the
proteinases as the targets. The lead compounds were
generated after hits were identiﬁed by virtual screening,
structure characterization, and medicinal chemistry. The
lead compounds were improved by iterations of structure-
based design, chemical synthesis, and functional assay. The
resulting inhibitors are shown to be capable of inhibiting
virus replication and restore host functions.
CS15.3 More and more coronaviruses after the SARS
epidemic: human coronavirus HKU1 and other
coronaviruses
P.C.Y. Woo*. Department of Microbiology, The University
of Hong Kong, Hong Kong S.A.R.
The recent SARS epidemic has boosted global interest in
the discovery of novel human and animal coronaviruses.
The number of coronavirus species with complete genomes
available has increased from nine in 2003 to about 30 in
2011, of which nine, including human coronavirus HKU1
(Betacoronavirus subgroup A), SARS-related Rhinolophus
bat coronavirus (Betacoronavirus subgroup B), Rhinolophus
bat coronavirus HKU2 (Alphacoronavirus), three bat
coronaviruses of two novel subgroups (C and D) in
Betacoronavirus, and three avian coronaviruses which
constitute a proposed novel genus (Deltacoronavirus) were
sequenced by our laboratory. Recently, we have also
developed a comprehensive database, CoVDB (http://
covdb.microbiology.hku.hk), of annotated coronavirus genes
and genomes, for rapid and accurate batch sequence
retrieval, the cornerstone and bottleneck for comparative
gene or genome analysis. With the increasing amount of
genomes available and the user-friendly database, easy
comparative genome analysis and more speciﬁc blast search
results can be generated for efﬁcient downstream analysis.
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Abstract not available
CS16.2 Improving survival in patients with
decompensated cirrhosis
D.N. Amarapurkar *. Department of Gastroenterology and
Hepatology, Bombay Hospital & Medical Research Centre,
Mumbai, India
Liver cirrhosis is deﬁned as development of regenerative
nodules surrounded by ﬁbrous septa in response to chronic
liver injury. This leads to vascular remodeling and giving rise
to portal hypertension and end stage liver disease. Liver
transplantation is the only treatment which improves both
longevity and quality of life in patients with decompensated
liver cirrhosis. However every patient with decompensated
liver cirrhosis is not eligible for transplantation and
it is not available for majority of the patients. Our
current understanding of natural history, pathophysiology
and treatment of complication has resulted in improved
management quality of life and life expectancy in patients
with decompensated liver cirrhosis. Median survival of
patients with compensated cirrhosis is 12 years while that
of decompensated patients is reduced to 2 years. Approx-
imately 5 to 7% of the patients change from compensated
stage to decompensated stage. Portal hypertension (PH)
is a universal consequence of cirrhosis responsible for
most of the complications like esophagogastric varices,
variceal bleeding, ascites, spontaneous bacterial peritonitis,
hepatorenal syndrome and hepatic encephalopathy. PH in
cirrhosis is deﬁned by hepatic venous pressure gradient
(HVPG) more than 5mm of mercury. HVPG is indirect
measure of portal pressure. Now it is clear that HVPG more
